In a research note, analyst Quintin Lai noted the recent FDA approval of the protein biomarker-based test developer's Galectin-3 test, as well as partnerships forged with several IVD instrument manufacturers that could speed adoption of the test.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.